Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer

NCT03187314 is registered in ClinicalTrials.gov with Hangzhou Cancer Hospital as lead sponsor.

NCT NCT03187314
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03187314 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Radiation Therapy With Anti-PD-1 Antibody SHR-1210 in Treating Patients With Unresectable Esophageal Cancer
Lead sponsor
Hangzhou Cancer Hospital
Phase
Phase 2
Overall status
Completed
Start date
June 14, 2017
Completion date
June 30, 2019
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal diseases, esophageal neoplasms, esophageal squamous cell carcinoma